SHANGHAI, China, BUDAPEST, Hungary and PRINCETON, N.J., Jan. 6 /PRNewswire/ -- WuXi AppTec, the operating company of WuXi PharmaTech, a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced its selection of H-Cube from ThalesNano Inc. for laboratory-based hydrogenation. WuXi joins all of the top 20 pharmaceutical companies worldwide that have introduced and adopted the H-Cube technology.
"WuXi Apptec is one of the largest CRO companies in the world, providing best in class services to pharmaceutical, biotechnology and medical device research and development industries. We are delighted to supply WuXi with our technology and services," commented Dr. Laszlo Urge, CEO of ThalesNano Inc.
"We are very pleased to deploy H-Cube. Hydrogenation in flow for drug discovery is a significantly more productive and safer approach than traditional batch-based techniques. We are looking forward to working with ThalesNano as we move to larger scale in the future," commented Shuhui Chen, Chief Scientific Officer of WuXi AppTec.
The H-Cube Continuous-flow Hydrogenation Reactor is a bench-top standalone hydrogenation device, uniquely combining continuous-flow microchemistry with endogenous on-demand hydrogen generation and a disposable catalyst cartridge system. Compared to conventional methods, it allows safer, faster and more cost-efficient hydrogenation with superior yield. The H-Cube and the other novel Cube series flow reactor systems developed by ThalesNano Inc. are showing tremendous benefits in the drug discovery process including shortened development time, increased cost efficiency and reduced environmental impact.
For more information please go to: www.thalesnano.com
About ThalesNano Inc.:
|SOURCE ThalesNano Inc.|
Copyright©2009 PR Newswire.
All rights reserved